487 filings
Page 5 of 25
CORRESP
yyy3v0
17 Mar 23
Correspondence with SEC
12:00am
CORRESP
6upq d9oq
17 Mar 23
Correspondence with SEC
12:00am
F-1/A
lqh d1n20x98
13 Mar 23
Registration statement (foreign) (amended)
9:18am
CORRESP
f61rb68ka o2zgl6afd
13 Mar 23
Correspondence with SEC
12:00am
CORRESP
zppfmgb nd0c2j
13 Mar 23
Correspondence with SEC
12:00am
FWP
2lts4sf
9 Mar 23
Free writing prospectus
4:31pm
6-K
wyx9yiub4 slna9ooqv
9 Mar 23
Current Report
4:30pm
FWP
j91gk f2j8
8 Mar 23
Free writing prospectus
10:10am
F-1/A
2fga s11nz
7 Mar 23
Registration statement (foreign) (amended)
1:02pm
F-1/A
wdc1bk1skgwpw8u ml
1 Mar 23
Registration statement (foreign) (amended)
1:02pm
F-1/A
rdmjphv 0ju
28 Feb 23
Registration statement (foreign) (amended)
4:12pm
CORRESP
4vylsdz3qb
28 Feb 23
Correspondence with SEC
12:00am
UPLOAD
mdvlh gw3
24 Feb 23
Letter from SEC
12:00am
6-K
fy4b2b
17 Feb 23
Report of Foreign Private Issuer
4:30pm
F-1
z4hi4d kuz
16 Feb 23
Registration statement (foreign)
10:17am
6-K
lna620u4qaxx5sbf
27 Jan 23
Report of Foreign Private Issuer
8:50am
6-K
bst649im
24 Jan 23
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
9:00am
SC 13D/A
eokvh73
18 Jan 23
Altamira Therapeutics / Meyer Thomas ownership change
4:30pm
424B4
1kscye
28 Dec 22
Prospectus supplement with pricing info
9:23am
EFFECT
mcr6wrin
28 Dec 22
Notice of effectiveness
12:15am